SLAMF7 and Miyoshi myopathy: Other anti-MM drugs, actually used in the clinical practice, have not shown any anti-angiogenic activity as a single agent, i.e., the anti-CD38 and anti-SLAMF7 mAbs (daratumumab, elotuzumab) and the conventional drug, doxorubicin, but have shown an appropriate/adequate efficacy in combination regimens with anti-angiogenic drugs [89,122,123,124].